SCHEMBL20023029

SCHEMBL20023029

O=C(CCCC(=O)c1ccc(Cl)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.51
MAPT P10636 5/20 0.51
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KMT2A Q03164 5/20 0.50
MEN1 O00255 4/20 0.50
HPGD P15428 1/20 0.50
DPP4 P27487 1/20 0.47
TDP1 Q9NUW8 3/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
ALDH1A1 P00352 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HSD11B1 P28845 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20023092 0.96 L3MBTL1 (0.50) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023040 0.90 TDP1 (0.56) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023032 0.87 TDP1 (0.58) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023036 0.86 TDP1 (0.61) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023063 0.86 USP5 (0.50) NPC1RAB9AKMT2AMEN1DPP4
SCHEMBL20023060 0.85 ERCC5 (0.50) NPC1RAB9AHPGDDPP4TDP1
SCHEMBL20023052 0.85 DPP4 (0.46) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023091 0.84 PDE4B (0.63) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023133 0.84 POLB (0.48) L3MBTL1MAPTNPC1RAB9AKMT2A
SCHEMBL20023049 0.84 HDAC1 (0.55) L3MBTL1MAPTNPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors GENZYME CORPORATION 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093981-A1 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors ASAH2, GBA1, GAA L3MBTL1 3762/4885MAPT 2401/4885NPC1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.